Solid dose delivery vehicle and methods of making same
View Patent ↗The present invention encompasses a solid dose delivery vehicle for ballistic administration of a bioactive material to subcutaneous and intradermal tissue, the delivery vehicle being sized and shaped for penetrating the epidermis. The delivery vehicle further comprises a stabilizing polyol glass loaded with the bioactive material and capable of releasing the bioactive material in situ. The present invention further includes methods of making and using the solid dose delivery vehicle of the invention.
1. A therapeutic composition in solid dose form comprising a bioactive material and a carbohydrate, wherein
a) the bioactive material is a protein,
b) the carbohydrate stabilizes the bioactive material in the presence of an organic solvent,
c) the therapeutic composition comprises therapeutic particles which contain said protein homogeneously distributed in solid solution in said carbohydrate in a glassy state,
d) the therapeutic composition is a powder having a particle size distribution suitable for pulmonary administration,
e) the therapeutic particles containing said protein and said carbohydrate in the solid solution remain in the glassy state when stored at 60° C. for one month,
f) the carbohydrate is selected from the group consisting of monosaccharides, disaccharides and sugar alcohols, and
g) the therapeutic particles have a mean particle size of 0.5 to 5 μm.
2. The therapeutic composition according to claim 1 , said therapeutic particles further comprising a physiologically acceptable inhibitor of the Maillard reaction.
3. The therapeutic composition according to claim 1 , said therapeutic particles additionally comprising a biodegradable glass.
4. The therapeutic composition according to claim 1 , wherein the particles have a mean particle size of 1 to 4 μm.
5. The therapeutic composition according to claim 1 , wherein the carbohydrate is a sugar alcohol.
6. The therapeutic composition according to claim 1 , wherein the carbohydrate is trehalose.
7. The therapeutic composition according to claim 1 , wherein the protein is insulin.
8. The therapeutic composition according to claim 7 , wherein the particles have a mean particle size of 1 to 4 μm.
9. The therapeutic composition according to claim 1 , wherein the protein is insulin and the carbohydrate is trehalose.
10. The therapeutic composition according to claim 9 , wherein the particles have a mean particle size of 1 to 4 μm.
11. The therapeutic composition according to claim 1 , said therapeutic particles further comprising an amino acid that is capable of inhibiting the Maillard reaction.
12. The therapeutic composition according to claim 1 , wherein the organic solvent is selected from the group consisting of ethanol, acetone, chloroform, acetonitrile, dichloromethane, and methanol.
13. The therapeutic composition according to claim 1 , wherein the therapeutic composition is suitable for delivering the bioactive material by transalveolar administration.
14. A therapeutic composition in solid dose form comprising a bioactive material and a carbohydrate, wherein
a) the bioactive material is a protein,
b) the bioactive material of the therapeutic composition is stabilized in the presence of an organic solvent,
c) the therapeutic composition comprises therapeutic particles which contain said protein homogeneously distributed in solid solution in said carbohydrate in a glassy state,
d) the therapeutic composition is a powder having a particle size distribution suitable for pulmonary administration,
e) the therapeutic composition further comprises a glass modifier, wherein the glass modifier is not the bioactive material,
f) the therapeutic particles containing the protein and the carbohydrate in the solid solution remain in the glassy state when stored at 60° C. for one month,
g) the carbohydrate is selected from the group consisting of monosaccharides, disaccharides and sugar alcohols, and
h) the therapeutic particles have a mean particle size of 0.5 to 5 μm.
15. The therapeutic composition according to claim 14 , wherein the glass modifier is a protein.
16. The therapeutic composition according to claim 14 , said therapeutic particles further comprising a physiologically acceptable inhibitor of the Maillard reaction.
17. The therapeutic composition according to claim 14 , said therapeutic particles additionally comprising a biodegradable glass.
18. The therapeutic composition according to claim 14 , wherein the particles have a mean particle size of 1 to 4 μm.
19. The therapeutic composition according to claim 14 , wherein the carbohydrate is a sugar alcohol.
20. The therapeutic composition according to claim 14 , wherein the carbohydrate is trehalose.
21. The therapeutic composition according to claim 14 , wherein the protein is insulin.
22. The therapeutic composition according to claim 21 , wherein the particles have a mean particle size of 1 to 4 μm.
23. The therapeutic composition according to claim 14 , wherein the protein is insulin and the carbohydrate is trehalose.
24. The therapeutic composition according to claim 23 , wherein the particles have a mean particle size of 1 to 4 μm.
25. The therapeutic composition according to claim 14 , said therapeutic particles further comprising an amino acid that is capable of inhibiting the Maillard reaction.
26. The therapeutic composition according to claim 14 , wherein the organic solvent is selected from the group consisting of ethanol, acetone, chloroform, acetonitrile, dichloromethane, and methanol.
27. The therapeutic composition according to claim 14 , wherein the therapeutic composition is suitable for delivering the bioactive material by transalveolar administration.
28. The therapeutic composition according to claim 1 , said therapeutic particles additionally comprising a water soluble glass.
29. The therapeutic composition according to claim 28 wherein the organic solvent is dichloromethane or chloroform.
30. The therapeutic composition according to claim 7 , said therapeutic particles additionally comprising a water soluble glass.
31. The therapeutic composition according to claim 1 , said therapeutic particles additionally comprising a water soluble glass.
32. The therapeutic composition according to claim 31 wherein the organic solvent is dichloromethane or chloroform.
33. The therapeutic composition according to claim 1 , said therapeutic particles additionally comprising a water soluble glass.
34. The therapeutic composition according to claim 1 , wherein the therapeutic composition is suitable for delivering the bioactive material by transalveolar administration.
35. The therapeutic composition according to claim 34 , wherein the carbohydrate is a sugar alcohol.
36. The therapeutic composition according to claim 35 , said therapeutic particles further comprising an amino acid that is capable of inhibiting the Maillard reaction
37. The therapeutic composition according to claim 14 , wherein the therapeutic composition is suitable for delivering the bioactive material by transalveolar administration.
38. The therapeutic composition according to claim 37 , wherein the carbohydrate is a sugar alcohol.
39. The therapeutic composition according to claim 38 , said therapeutic particles further comprising and amino acid that is capable of inhibiting the Maillard reaction.